Texas Oncology - San Antonio Medical Center

San Antonio, TX

Sorting 2 by

Accepting patients

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

Teclistamab or Talquetamab

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2
  • Has results